2022
Analysis of Tumor Burden as a Biomarker for Patient Survival with Neuroendocrine Tumor Liver Metastases Undergoing Intra-Arterial Therapies: A Single-Center Retrospective Analysis
Miszczuk M, Chapiro J, Do Minh D, van Breugel JMM, Smolka S, Rexha I, Tegel B, Lin M, Savic LJ, Hong K, Georgiades C, Nezami N. Analysis of Tumor Burden as a Biomarker for Patient Survival with Neuroendocrine Tumor Liver Metastases Undergoing Intra-Arterial Therapies: A Single-Center Retrospective Analysis. CardioVascular And Interventional Radiology 2022, 45: 1494-1502. PMID: 35941241, PMCID: PMC9587516, DOI: 10.1007/s00270-022-03209-9.Peer-Reviewed Original ResearchConceptsNeuroendocrine tumor liver metastasesMedian overall survivalIntra-arterial therapyLow tumor burdenTumor burdenOverall survivalLiver metastasesPrognostic factorsTumor diameterTB groupLonger median overall survivalRetrospective single-center analysisSingle-center retrospective analysisHigh TB groupLow TB groupRespective hazard ratiosHigh tumor burdenSingle-center analysisIndependent prognostic factorStrong prognostic factorDrug-eluting beadsLargest liver lesionPrediction of survivalHazard ratioPatient survival
2021
Comparison of metabolic and immunologic responses to transarterial chemoembolization with different chemoembolic regimens in a rabbit VX2 liver tumor model
Doemel LA, Santana JG, Savic LJ, Gaupp FML, Borde T, Petukhova-Greenstein A, Kucukkaya AS, Schobert IT, Hamm CA, Gebauer B, Walsh JJ, Rexha I, Hyder F, Lin M, Madoff DC, Schlachter T, Chapiro J, Coman D. Comparison of metabolic and immunologic responses to transarterial chemoembolization with different chemoembolic regimens in a rabbit VX2 liver tumor model. European Radiology 2021, 32: 2437-2447. PMID: 34718844, PMCID: PMC9359419, DOI: 10.1007/s00330-021-08337-3.Peer-Reviewed Original ResearchConceptsDrug-eluting embolicsImmune cell infiltrationAntigen-presenting cellsBicarbonate infusionConventional TACEDEE-TACETransarterial chemotherapyCell infiltrationImmune cellsPeritumoral infiltrationT lymphocytesIntratumoral immune cell infiltrationTumor modelRabbit VX2 liver tumor modelImmunological tumor microenvironmentVX2 liver tumor modelIntra-arterial therapyIntra-arterial treatmentRabbit VX2 tumor modelLiver tumor modelTumor-bearing rabbitsVX2 tumor modelMann-Whitney U testIntratumoral presenceTransarterial chemoembolizationIdentifying enhancement-based staging markers on baseline MRI in patients with colorectal cancer liver metastases undergoing intra-arterial tumor therapy
Ghani MA, Fereydooni A, Chen E, Letzen B, Laage-Gaupp F, Nezami N, Deng Y, Gan G, Thakur V, Lin M, Papademetris X, Schernthaner RE, Huber S, Chapiro J, Hong K, Georgiades C. Identifying enhancement-based staging markers on baseline MRI in patients with colorectal cancer liver metastases undergoing intra-arterial tumor therapy. European Radiology 2021, 31: 8858-8867. PMID: 34061209, PMCID: PMC8848338, DOI: 10.1007/s00330-021-08058-7.Peer-Reviewed Original ResearchConceptsColorectal cancer liver metastasesCancer liver metastasesTotal tumor volumeIntra-arterial therapyTotal liver volumeLiver metastasesTumor volumeTumor burdenTumor diameterPatient survivalBaseline MRILiver volumeMultivariable Cox proportional hazards modelsKaplan-Meier survival curvesWhole liverCox proportional hazards modelKaplan-Meier methodPrognostic staging systemSurvival of patientsColorectal cancer metastasisMethodsThis retrospective studyPre-treatment MRIProportional hazards modelAppropriate cutoff valueHR 1.7
2018
Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma.
Abajian A, Murali N, Savic LJ, Laage-Gaupp FM, Nezami N, Duncan JS, Schlachter T, Lin M, Geschwind JF, Chapiro J. Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma. Journal Of Visualized Experiments 2018 PMID: 30371657, PMCID: PMC6235502, DOI: 10.3791/58382.Peer-Reviewed Original ResearchConceptsIntra-arterial therapyN patientsHepatocellular carcinomaTrans-arterial therapiesIntra-arterial treatmentCohort of patientsStandard of careLikelihood of responseClinical research questionsSurgical resectionNew patientsTreatment responseUnivariate associationsPatientsTraining patientsInterventional radiologyTherapyCarcinomaTreatmentImage-guided therapyOutcomesFinal modelImaging dataResectionResponsePredicting Treatment Response to Intra-arterial Therapies for Hepatocellular Carcinoma with the Use of Supervised Machine Learning—An Artificial Intelligence Concept
Abajian A, Murali N, Savic LJ, Laage-Gaupp FM, Nezami N, Duncan JS, Schlachter T, Lin M, Geschwind JF, Chapiro J. Predicting Treatment Response to Intra-arterial Therapies for Hepatocellular Carcinoma with the Use of Supervised Machine Learning—An Artificial Intelligence Concept. Journal Of Vascular And Interventional Radiology 2018, 29: 850-857.e1. PMID: 29548875, PMCID: PMC5970021, DOI: 10.1016/j.jvir.2018.01.769.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsCarcinoma, HepatocellularChemoembolization, TherapeuticContrast MediaDoxorubicinEthiodized OilFemaleHumansLiver NeoplasmsMachine LearningMagnetic Resonance ImagingMaleMiddle AgedNeoplasm StagingPredictive Value of TestsRetrospective StudiesSensitivity and SpecificityTreatment OutcomeConceptsTransarterial chemoembolizationHepatocellular carcinomaTreatment responseLogistic regressionClinical patient dataPatient dataIntra-arterial therapyQuantitative European AssociationMagnetic resonance imagingLiver criteriaBaseline imagingClinical variablesTumor responseTherapeutic featuresTreatment respondersBaseline MRClinical informationImaging variablesChemoembolizationTherapeutic outcomesResonance imagingResponse criteriaEuropean AssociationPatientsMR imaging
2017
Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model
Do Minh D, Chapiro J, Gorodetski B, Huang Q, Liu C, Smolka S, Savic LJ, Wainstejn D, Lin M, Schlachter T, Gebauer B, Geschwind JF. Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model. European Radiology 2017, 27: 4995-5005. PMID: 28677067, PMCID: PMC5675796, DOI: 10.1007/s00330-017-4856-2.Peer-Reviewed Original ResearchConceptsMultivariate Cox proportional hazards modelConventional transarterial chemoembolisationMedian overall survivalPropensity score analysisHepatic progression-free survivalDrug-eluting beads TACEYttrium-90 radioembolisationProgression-free survivalDEB-TACELiver metastasesOverall survivalBeads TACENeuroendocrine tumor liver metastasesWorld Health Organization criteriaCox proportional hazards modelIntra-arterial therapyMethodsThis retrospective analysisResponse Evaluation CriteriaScore analysisSignificant survival benefitLonger overall survivalGastroenteropancreatic neuroendocrine tumorsLog-rank testEntire study populationProportional hazards modelIntra-arterial embolotherapy for intrahepatic cholangiocarcinoma: update and future prospects
Savic LJ, Chapiro J, Geschwind JH. Intra-arterial embolotherapy for intrahepatic cholangiocarcinoma: update and future prospects. HepatoBiliary Surgery And Nutrition 2017, 6: 7-21. PMID: 28261591, PMCID: PMC5332218, DOI: 10.21037/hbsn.2016.11.02.Peer-Reviewed Original ResearchIntra-arterial therapyConventional transcatheter arterial chemoembolizationLoco-regional therapyIntrahepatic cholangiocarcinomaOnly curative treatment optionUnresectable intrahepatic cholangiocarcinomaCurative treatment optionIntra-arterial administrationTranscatheter arterial chemoembolizationConversion of patientsDrug-eluting beadsTreatment escalationY90-RESystemic chemotherapyDEB-TACEPalliative treatmentProspective trialSurvival benefitArterial chemoembolizationCombination regimensPalliative approachClinical evidenceLate presentationPoor prognosisTherapeutic options
2016
Intra-arterial therapies for liver cancer: assessing tumor response
Stroehl YW, Letzen BS, van Breugel JM, Geschwind JF, Chapiro J. Intra-arterial therapies for liver cancer: assessing tumor response. Expert Review Of Anticancer Therapy 2016, 17: 119-127. PMID: 27983883, DOI: 10.1080/14737140.2017.1273775.Peer-Reviewed Original ResearchValidation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy
Sohn JH, Duran R, Zhao Y, Fleckenstein F, Chapiro J, Sahu S, Schernthaner RE, Qian T, Lee H, Zhao L, Hamilton J, Frangakis C, Lin M, Salem R, Geschwind JF. Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy. Clinical Gastroenterology And Hepatology 2016, 15: 746-755.e4. PMID: 27847278, PMCID: PMC5823259, DOI: 10.1016/j.cgh.2016.10.036.Peer-Reviewed Original ResearchConceptsLiver Cancer staging systemIntra-arterial therapyCancer (AJCC) staging systemHong Kong Liver Cancer (HKLC) staging systemStaging systemHepatocellular carcinomaSurvival timeBCLC systemPatient survival timeHKLC systemRetrospective analysisBarcelona Clinic Liver Cancer (BCLC) staging systemStage IVUnresectable hepatocellular carcinomaOverall survival timeKaplan-Meier estimatesDate of deathHepatitis CSystemic chemotherapyHepatitis BMost patientsUnresectable tumorsEntire cohortC-statisticHCC stageImproved Visibility of Metastatic Disease in the Liver During Intra-Arterial Therapy Using Delayed Arterial Phase Cone-Beam CT
Schernthaner RE, Haroun RR, Duran R, Lee H, Sahu S, Sohn JH, Chapiro J, Zhao Y, Gorodetski B, Fleckenstein F, Smolka S, Radaelli A, van der Bom IM, Lin M, Geschwind JF. Improved Visibility of Metastatic Disease in the Liver During Intra-Arterial Therapy Using Delayed Arterial Phase Cone-Beam CT. CardioVascular And Interventional Radiology 2016, 39: 1429-1437. PMID: 27380872, PMCID: PMC5009166, DOI: 10.1007/s00270-016-1406-2.Peer-Reviewed Original ResearchConceptsIntra-arterial therapyDigital subtraction angiographyLiver metastasesDP-CBCTCone-beam CTDual-phase cone-beam CTContrast-enhanced magnetic resonance imagingSarcoma liver metastasesTumor-feeding arteriesMagnetic resonance imagingContrast agent injectionMetastatic diseaseMethodsThis IRBRetrospective studyCRCLMClinical impactArterial phaseCE-MRIDepiction rateResonance imagingAgent injectionSubtraction angiographyMetastasisTherapyHigh rate
2015
Targeting glucose metabolism in cancer: a new class of agents for loco-regional and systemic therapy of liver cancer and beyond?
Savic LJ, Chapiro J, Duwe G, Geschwind J. Targeting glucose metabolism in cancer: a new class of agents for loco-regional and systemic therapy of liver cancer and beyond? Hepatic Oncology 2015, 3: 19-28. PMID: 26989470, PMCID: PMC4792180, DOI: 10.2217/hep.15.36.Peer-Reviewed Original ResearchIntra-arterial therapyHepatocellular carcinomaCancer-related deathUnresectable diseaseCancer cell metabolismSystemic therapyTherapeutic optionsTumor controlPrevalent cancerLiver cancerGlucose metabolismAntiglycolytic agentsTumor growthSystemic toxicitySelective anticancer therapyTherapyAnticancer therapyCancerNew targetsWarburg effectMolecular featuresAntiglycolytic drugsCell metabolismDelivery methodsMetabolismSystematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions
Duran R, Chapiro J, Schernthaner RE, Geschwind JF. Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions. British Journal Of Radiology 2015, 88: 20140564. PMID: 25978585, PMCID: PMC4651391, DOI: 10.1259/bjr.20140564.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAntineoplastic AgentsCarcinoma, HepatocellularCatheter AblationChemoembolization, TherapeuticCombined Modality TherapyDiffusion of InnovationEmbolization, TherapeuticFemaleForecastingHumansInfusions, Intra-ArterialLiver NeoplasmsMaleMicrospheresNiacinamidePatient SelectionPhenylurea CompoundsRadiopharmaceuticalsSorafenibYttrium RadioisotopesConceptsIntra-arterial therapyHepatocellular carcinomaSecondary liver malignanciesManagement of patientsHealthy liver tissueLocoregional therapyLiver malignanciesClinical rationaleHigh doseInterventional oncologySystematic reviewAnticancer treatmentLiver tissueInvasive natureClinical achievementsChemoresistant cancersTherapyMedical communityPatientsCarcinomaTreatmentPivotal roleMalignancySorafenibCancerEarly survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver
Chapiro J, Duran R, Lin M, Schernthaner R, Lesage D, Wang Z, Savic LJ, Geschwind JF. Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver. European Radiology 2015, 25: 1993-2003. PMID: 25636420, PMCID: PMC4458393, DOI: 10.1007/s00330-015-3595-5.Peer-Reviewed Original ResearchConceptsIntra-arterial therapyColorectal liver metastasesTransarterial chemoembolizationPatient survivalHazard ratioLiver metastasesOverall survivalResponse assessmentVolumetric tumour response assessmentCox proportional hazard ratiosMethodsThis retrospective analysisProportional hazard ratiosKaplan-Meier analysisColorectal cancer metastasisTumor response assessmentTumor analysisEarly survival predictionQuantitative MRI assessmentMRI assessmentTumor responseLesion volumeRetrospective analysisMultivariate analysisPatientsPredictive role
2014
Combination of intra-arterial therapies and sorafenib: Is there a clinical benefit?
Chapiro J, Duran R, Geschwind JF. Combination of intra-arterial therapies and sorafenib: Is there a clinical benefit? La Radiologia Medica 2014, 119: 476-482. PMID: 24894921, DOI: 10.1007/s11547-014-0413-0.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBiomarkers, TumorCarcinoma, HepatocellularChemoembolization, TherapeuticEmbolization, TherapeuticHepatectomyHepatic ArteryHumansInfusions, Intra-ArterialLiver NeoplasmsMicrospheresNeoplasm StagingNiacinamidePhenylurea CompoundsRadiography, InterventionalSorafenibSurvival RateConceptsIntra-arterial therapySurvival benefitIntroduction of sorafenibLoco-regional approachesAdvanced stage diseaseSignificant survival benefitUnresectable hepatocellular carcinomaLocal tumor controlTreatment of patientsSequence of administrationConventional systemic chemotherapyInternational clinical trialsOral monotherapySystemic chemotherapyExciting new optionsClinical outcomesTransarterial chemoembolizationClinical benefitSafety profileTumor controlClinical trialsHepatocellular carcinomaNovel agentsPotential biomarkersSystemic toxicity
2013
Percutaneous therapies of hepatocellular carcinoma—an update
Chapiro J, Geschwind JF. Percutaneous therapies of hepatocellular carcinoma—an update. Chinese Clinical Oncology 2013, 2: 36-36. PMID: 25841915, DOI: 10.3978/j.issn.2304-3865.2013.07.04.Peer-Reviewed Original ResearchIntra-arterial therapyHepatocellular carcinomaSpecific therapeutic algorithmsAvailable clinical evidenceEarly-stage diseaseIntra-arterial approachEnd-stage diseaseLocal tumor controlPrimary liver cancerTreatment of patientsTherapeutic algorithmEthanol ablationTransarterial chemoembolizationClinical evidencePatient groupTumor controlPercutaneous techniquesRadiofrequency ablationSuch therapyTherapeutic spectrumAblative techniquesPercutaneous therapyLiver cancerSystemic toxicityTherapy